Halozyme Therapeutics, Inc.: director Bernadette Connaughton received 3,796 shares

What happened Bernadette Connaughton, a director of Halozyme Therapeutics, Inc., was granted 3,796 restricted stock units (RSUs) on May 5, 2026 at an acquisition price of $0.00 per share (total $0).

Key details

• Transaction date and price: May 5, 2026; grant price $0.00 per share.
• Shares acquired: 3,796 RSUs (each RSU represents the right to receive one share).
• Vesting: the RSUs will vest in full on the earlier of May 5, 2027 and the date of the issuer's next annual meeting of stockholders.
• Amendment: this Form 4/A amends the Form 4 filed on May 7, 2026 to correct the number of RSUs acquired (originally reported as 6,796; corrected to 3,796) and the amount of securities beneficially owned following the transaction.
• Shares owned after the transaction: the filing states the amount was revised in the amendment; the amended total beneficial ownership is not stated here.
• Timeliness: the filing is an amendment to the Form 4 filed May 7, 2026 (no late filing designation noted in this summary).

Why it may matter

• This was a grant of RSUs under the issuer's director compensation program, not an open-market purchase or sale.
• The grant is subject to vesting conditions described above.
  This filing does not show why the insider traded or why the company acted.